SLC5A2 and type 2 diabetes mellitus: A meta-analysis of 42 trials with a total of 61,076 patients with type 2 diabetes showed that the risk of ischemic stroke was not reduced after SGLT2 inhibitor treatment in patients with type 2 diabetes (OR = 0.95, 95% CI 0.85–1.07, p = 0.42) [39].